Ginkgo Bioworks (NYSE: DNA) stock has had a rough 12 months, falling 88%, and undergoing a reverse stock split on Aug. 20 that left its shares down by around 18% in the aftermath. Depending on which view of the company you subscribe to, things could keep getting worse for shareholders over the next couple of years -- or they could get a lot better.

Let's game out a few scenarios so that you can understand whether this stock is worth taking a chance on, or whether it's too risky to touch given your preferences.

The optimistic case for Ginkgo is that it'll succeed in finding a way to slash its costs while also continuing to gain traction with its customers within the next 24 months, thereby moderately boosting its revenue and generating steadily growing operational profits at the same time. Management's primary goal at the moment is to break even on its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) before the close of 2026.

Continue reading

Source Fool.com